Phase 3 N=100 Use of a Modified Propofol Emulsion in Adults
Anesthesia
Primary: Incidence of Expression of Pain During Injection — 1; 7 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=77 Efficacy and Safety of Basiliximab, Cyclosporine/Cyclosporine Microemulsion, and Steroids in Pediatric de Novo Liver Transplant Recipients Avoiding Intraoperative Steroids
Liver Transplantation · Infection
Primary: Number of Participants With at Least One Biopsy Proven Acute Rejection (BPAR) Episode, Graft Loss or Death Within the First Three Months Post-transplantation — 8; 15…
Phase 3 N=408 Locomotor Experience Applied Post Stroke Trial
Stroke
Primary: Percentage of Patients Who Successfully Improved Functional Level of Walking at 1 Year Post-stroke — 50.4; 53.8; 51.6 percent of participants — p=0.481
Phase 3 N=2,312 A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children
Healthy or Stable Chronic Illness
Primary: The 4 Post-dose Strain-specific Serum Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titers (GMT) in the Q/LAIV (MEDI3250) Arm Are Noninferior to Those in the…
Phase 3 N=485 Trial of Decitabine in Patients With Acute Myeloid Leukemia
Acute Myeloid Leukemia
Primary: Overall Survival in Patients 65 Years or Older Who Have Newly Diagnosed de Novo or Secondary AML. — 5.0; 7.7 months — p=0.1079
Phase 3 N=568 Evaluate Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Inadequate Glycemic Control
Type 2 Diabetes
Primary: Absolute Change From Baseline to Week 24 in Glycosylated Haemoglobin A1c (HbA1c) — 8.15; 8.14; 7.25; 7.75 percent — p=<0.0001
Phase 3 N=164 Efficacy and Safety of 4.0 mg/kg Sugammadex at 1-2 PTC in Chinese and European Subjects (Study 19.4.335)(P05775AM1)(COMPLETED)
Anesthesia, General · Neuromuscular Blockade
Primary: Time From Start of Administration of Sugammadex to Recovery of the T4/T1 Ratio to 0.9 — 2.3; 1.4 minutes
Phase 3 N=1,053 Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects
Pneumococcal Infections
Primary: Percentage of Participants With Pre-specified Local Reactions — 14.3; 12.6; 6.5; 1.1 Percentage of Participants
Phase 3 N=42 Treatment of Adolescent Polycystic Ovary Syndrome (PCOS)
Polycystic Ovary Syndrome
Primary: Measure Number of Adolescent Girls With PCOS Who Can be Successfully Recruited Into a Randomized Clinical Trial That Includes Lifestyle Modification — 10; 11; 11; 10…
Phase 3 N=326 A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)
Acute Myelogenous Leukemia
Primary: Overall Survival - Overall and by Calculated Strata (CSR 7-April-11) — 6.6; 6.4; 5.1; 5.5 months — p=0.9951
Phase 3 N=357 Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis
Conjunctivitis · Keratitis · Blepharitis
Primary: Signs and Symptoms Composite Score - Change From Baseline to Day 15 - PP Population — -11.63; -12.41 Scores on a scale
Phase 3 N=379 Gel-200 Versus Placebo in Osteoarthritis of the Knee
Osteoarthritis of the Knee
Primary: Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Visual Analog Scale (VAS) Pain Subscore — 27.8; 22.6 scores on a scale…
Phase 3 N=319 Trial of Caldolor for Treatment of Pain in Post-Operative Adult Patients
Pain
Primary: Change in the Patient Demand for the Narcotic Analgesic, Morphine, Post Surgery — 57.0; 48.7 milligrams
Phase 3 N=122 Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids
Kidney Transplantation
Primary: Core Study: Number of Patients With Composite Efficacy Endpoint — 7; 7; 3; 5 Participants
Phase 3 N=2,856 Secondary Prevention of Venous Thrombo Embolism (VTE).
Thromboembolism
Primary: Composite of Recurrent VTE or VTE Death at 36 Months — 26; 18; 1404; 1408 Participants — p=0.0137